These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 24809337

  • 1. ▼Nalmefene for alcohol dependence.
    Drug Ther Bull; 2014 May; 52(5):54-7. PubMed ID: 24809337
    [Abstract] [Full Text] [Related]

  • 2. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J, Morgan MY.
    Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485
    [Abstract] [Full Text] [Related]

  • 3. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
    Mann K, Bladström A, Torup L, Gual A, van den Brink W.
    Biol Psychiatry; 2013 Apr 15; 73(8):706-13. PubMed ID: 23237314
    [Abstract] [Full Text] [Related]

  • 4. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
    Soyka M, Friede M, Schnitker J.
    Pharmacopsychiatry; 2016 Mar 15; 49(2):66-75. PubMed ID: 26845589
    [Abstract] [Full Text] [Related]

  • 5. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun 15; 23(150):150-2. PubMed ID: 25121147
    [Abstract] [Full Text] [Related]

  • 6. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
    Gual A, He Y, Torup L, van den Brink W, Mann K, ESENSE 2 Study Group.
    Eur Neuropsychopharmacol; 2013 Nov 15; 23(11):1432-42. PubMed ID: 23562264
    [Abstract] [Full Text] [Related]

  • 7. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
    Karhuvaara S, Simojoki K, Virta A, Rosberg M, Löyttyniemi E, Nurminen T, Kallio A, Mäkelä R.
    Alcohol Clin Exp Res; 2007 Jul 15; 31(7):1179-87. PubMed ID: 17451401
    [Abstract] [Full Text] [Related]

  • 8. Evaluation in alcohol use disorders - insights from the nalmefene experience.
    Naudet F, Palpacuer C, Boussageon R, Laviolle B.
    BMC Med; 2016 Aug 18; 14(1):119. PubMed ID: 27534932
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG.
    Adicciones; 2015 Sep 29; 27(3):214-30. PubMed ID: 26437315
    [Abstract] [Full Text] [Related]

  • 12. Safety of nalmefene for the treatment of alcohol use disorder: an update.
    López-Pelayo H, Zuluaga P, Caballeria E, Van den Brink W, Mann K, Gual A.
    Expert Opin Drug Saf; 2020 Jan 29; 19(1):9-17. PubMed ID: 31868031
    [Abstract] [Full Text] [Related]

  • 13. Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.
    Barrio P, Ortega L, Guardia J, Roncero C, Yuguero L, Gual A.
    Clin Drug Investig; 2018 Feb 29; 38(2):147-155. PubMed ID: 29080208
    [Abstract] [Full Text] [Related]

  • 14. [Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
    Dahmke H, Kupferschmidt H, Kullak-Ublick GA, Weiler S.
    Praxis (Bern 1994); 2015 Oct 14; 104(21):1129-34. PubMed ID: 26463904
    [Abstract] [Full Text] [Related]

  • 15. A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence.
    Laramée P, Millier A, Rahhali N, Cristeau O, Aballéa S, François C, Chalem Y, Toumi M, Rehm J.
    Appl Health Econ Health Policy; 2016 Aug 14; 14(4):493-505. PubMed ID: 27283839
    [Abstract] [Full Text] [Related]

  • 16. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
    Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, Naudet F.
    Addiction; 2018 Feb 14; 113(2):220-237. PubMed ID: 28940866
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study.
    Di Nicola M, De Filippis S, Martinotti G, De Risio L, Pettorruso M, De Persis S, Maremmani AGI, Maremmani I, di Giannantonio M, Janiri L.
    Adv Ther; 2017 Jul 14; 34(7):1636-1649. PubMed ID: 28540656
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Nalmefene for the treatment of alcohol dependence: a current update.
    Soyka M.
    Int J Neuropsychopharmacol; 2014 Apr 14; 17(4):675-84. PubMed ID: 24246244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.